Patients with resected stage 3 or 4 melanoma treated with immune-oncology agents demonstrated significantly higher cure rates ...

Patients with wild-type metastatic melanoma that progressed on frontline PD-1 inhibition had almost a 2-year median overall ...

Vemurafenib (ZELBORAF, Hoffmann-La Roche Inc; Figure 1) is a first-in-class selective inhibitor of the BRAF serine-threonine kinase, FDA approved for the treatment of metastatic melanoma harboring ...

We played a major role in characterising the BRAF gene and its role in cancer, increasing our understanding of malignant melanoma. Our work on the gene ... selective BRAF inhibitors developed another ...

The study will also evaluate the effect of the combination on tumor biomarkers, safety and anti-cancer activity in patients with BRAFV600 wild type melanoma ... melanoma with BRAF V600E or ...

Melanoma is a type of skin cancer. When it spreads to other places in your body, it's called metastatic, or advanced. If you have fair skin or you’ve spent lots of time in the sun, it’s a ...

A new case report was published in Oncotarget's Volume 15 on October 11, 2024, entitled "Complete response to encorafenib plus binimetinib in a BRAF V600E-mutant metastasic malignant glomus tumor." As ...

Amtagvi Infusions: A total of 146 patients have been infused with Amtagvi since the first commercial infusion in April 2024, including 25 patients infused in the second quarter, 82 patients infused in ...

The official radio flagship home of the Minnesota Wild. Since the 2011-12 NHL season, KFAN has broadcast all Wild preseason, regular season and Stanley Cup Playoff games on the State of Hockey's ...

"Instead, ipilimumab treatment could be of great value in patients with BRAF/NRAS wild-type melanoma and without brain metastases, with several benefits to long-term survival, although a larger ...